Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 300 of 399 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/29/19
End: 11/29/26
Due: 11/29/27
Phase: N/A
Priority: Normal
Start: 08/13/20
End: 03/14/26
Due: 03/14/27
Phase: N/A
Priority: Normal
Start: 10/31/12
End: 04/08/17
Due: 04/08/18
Phase: N/A
Priority: Normal
Start: 01/14/09
End: 03/13/19
Due: 03/13/20
Phase: N/A
Priority: Normal
Start: 12/04/20
End: 11/18/22
Due: 11/18/23
Phase: N/A
Priority: Normal
Start: 08/31/07
End: 07/31/10
Due: 07/31/11
Phase: N/A
Priority: Normal
Start: 05/31/01
End: 01/31/03
Due: 01/31/04
Phase: N/A
Priority: Normal
Start: 12/19/22
End: 12/15/26
Due: 12/15/27
Phase: N/A
Priority: Normal
Start: 10/14/14
End: 03/17/17
Due: 03/17/18
Phase: N/A
Priority: Normal
Start: 04/30/97
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/04/13
End: 05/06/20
Due: 05/06/21
Phase: N/A
Priority: Normal
Start: 06/30/02
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 01/31/03
End: 09/30/05
Due: 09/30/06
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase: N/A
Priority: Normal
Start: 05/31/15
End: 06/30/16
Due: 06/30/17
Phase: N/A
Priority: Normal
Start: 06/15/25
End: 03/15/28
Due: 03/15/29
Phase: N/A
Priority: Normal
Start: 12/19/24
End: 12/15/27
Due: 12/15/28
Phase: N/A
Priority: Normal
Start: 05/04/15
End: 06/30/25
Due: 06/30/26
Phase: N/A
Priority: Normal
Start: 10/01/25
End: 10/01/27
Due: 10/01/28
Phase: N/A
Priority: Normal
Start: 12/19/19
End: 11/16/22
Due: 11/16/23
Phase: N/A
Priority: Normal
Start: 01/31/15
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 10/04/13
End: 02/23/18
Due: 02/23/19
Phase: N/A
Priority: Normal
Start: 05/31/12
End: 06/30/16
Due: 06/30/17
Phase: N/A
Priority: Normal
Start: 07/29/21
End: 01/29/27
Due: 01/29/28
Phase: N/A
Priority: Normal
Start: 10/21/21
End: 01/25/23
Due: 01/25/24
Phase: N/A
Priority: Normal
Start: 10/06/17
End: 06/02/22
Due: 06/02/23